Paula Soteropoulos

Operates as nonprofit organization that provides young people to build skills for college and careers

Operates as a clinical-stage biotech company that delivers groundbreaking therapies

Develops therapies for severe autoimmune diseases

5AM Ventures invests in companies located in the US with an investment size ranging from $20 to $30 million. The firm targets companies operating in the fields of life sciences. It provides financing for early stage and corporate spin-out capital requirements and also makes co-investments.

Operates as a clinical-stage genomic vivo cellular medicines company

Kyowa Kirin, Inc. is a specialty pharmaceutical company dedicated to developing specialty medicines primarily for rare, serious, and underserved diseases. The company is based in Bedminster, NJ. The company focuses on therapeutic areas including bone and mineral diseases, hematologic malignancies and refractory hematologic diseases, nephrology, oncology, immunology, allergy, and neurology. Kyowa Kirin advances modalities such as next-generation antibody therapeutics, hematopoietic stem cell gene therapies, cell therapies, and proprietary antibody technologies. The company operates a network with subsidiaries and research facilities across multiple regions and is expanding manufacturing capacity to support late-stage biologic therapies. Kyowa Kirin emphasizes quality assurance, compliance, and patient safety throughout drug development, clinical trials, manufacturing, and commercialization. The company's clinical research prioritizes diversity and transparency, and they support patient communities and advocacy groups through research and educational initiatives. Partnerships with academic institutions, biotech, pharmaceutical companies, and patient organizations are central to their strategy. The company's portfolio includes medicines such as Crysvita, Poteligeo, Nourianz, and Komzifti, supported by patient assistance programs and expanded access policies.